Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Brand-name prescription medicine

Imkeldi

Generic name: Imatinib mesylate

FDA application holder: Shorla Oncology

Official data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the NDC Directory, Drugs@FDA, the official labels and recall reports; pharmacy costs come from the Centers for Medicare & Medicaid Services (CMS). Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or switch any medicine, including a switch between a brand and a generic.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Imkeldi?
Imkeldi is a brand name of Imatinib mesylate, a prescription medicine. The FDA NDC Directory lists 1 Imkeldi product in 1 strength and form.
Who makes Imkeldi?
Shorla Oncology holds the FDA application for Imkeldi (NDA219097, approved November 22, 2024).
Is there a generic or store brand of Imkeldi?
Other products of Imatinib mesylate are listed with the FDA, but none in exactly the same strength and form as a Imkeldi product.
Has Imkeldi been recalled?
No recall linked to Imkeldi products (by their NDC code or label) appears in the FDA enforcement reports we use.

What Imkeldi is

Each Imkeldi product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.

Imatinib mesylate · prescription medicine

Strength and formProduct namesSame medicine, other namesLabel
imatinib mesylate 80 mg/mL
solution (oral)
Imkeldi None listed —

Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Imatinib mesylate →

FDA approval

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
FDA applications of Imkeldi products (Drugs@FDA)
ApplicationHolderFirst approvedProducts
NDA219097Shorla OncologyNovember 22, 20241

Companies that list Imkeldi

The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Imkeldi products.

Recalls

No recall linked to Imkeldi products (by their NDC code or label) appears in the FDA enforcement reports.

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026

Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.

Report an error → · Information for medicine makers